These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 35844552)

  • 1. Role of Fc Core Fucosylation in the Effector Function of IgG1 Antibodies.
    Golay J; Andrea AE; Cattaneo I
    Front Immunol; 2022; 13():929895. PubMed ID: 35844552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The "less-is-more" in therapeutic antibodies: Afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity.
    Pereira NA; Chan KF; Lin PC; Song Z
    MAbs; 2018 Jul; 10(5):693-711. PubMed ID: 29733746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycan engineering reveals interrelated effects of terminal galactose and core fucose on antibody-dependent cell-mediated cytotoxicity.
    Zhang Q; Joubert MK; Polozova A; De Guzman R; Lakamsani K; Kinderman F; Xiang D; Shami A; Miscalichi N; Flynn GC; Kuhns S
    Biotechnol Prog; 2020 Nov; 36(6):e3045. PubMed ID: 32627435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fc-galactosylation modulates antibody-dependent cellular cytotoxicity of therapeutic antibodies.
    Thomann M; Reckermann K; Reusch D; Prasser J; Tejada ML
    Mol Immunol; 2016 May; 73():69-75. PubMed ID: 27058641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody Fucosylation Lowers the FcγRIIIa/CD16a Affinity by Limiting the Conformations Sampled by the N162-Glycan.
    Falconer DJ; Subedi GP; Marcella AM; Barb AW
    ACS Chem Biol; 2018 Aug; 13(8):2179-2189. PubMed ID: 30016589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prominent lack of IgG1-Fc fucosylation of platelet alloantibodies in pregnancy.
    Kapur R; Kustiawan I; Vestrheim A; Koeleman CA; Visser R; Einarsdottir HK; Porcelijn L; Jackson D; Kumpel B; Deelder AM; Blank D; Skogen B; Killie MK; Michaelsen TE; de Haas M; Rispens T; van der Schoot CE; Wuhrer M; Vidarsson G
    Blood; 2014 Jan; 123(4):471-80. PubMed ID: 24243971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased in vivo effector function of human IgG4 isotype antibodies through afucosylation.
    Gong Q; Hazen M; Marshall B; Crowell SR; Ou Q; Wong AW; Phung W; Vernes JM; Meng YG; Tejada M; Andersen D; Kelley RF
    MAbs; 2016; 8(6):1098-106. PubMed ID: 27216702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells.
    Peipp M; Lammerts van Bueren JJ; Schneider-Merck T; Bleeker WW; Dechant M; Beyer T; Repp R; van Berkel PH; Vink T; van de Winkel JG; Parren PW; Valerius T
    Blood; 2008 Sep; 112(6):2390-9. PubMed ID: 18566325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conformational effects of N-glycan core fucosylation of immunoglobulin G Fc region on its interaction with Fcγ receptor IIIa.
    Sakae Y; Satoh T; Yagi H; Yanaka S; Yamaguchi T; Isoda Y; Iida S; Okamoto Y; Kato K
    Sci Rep; 2017 Oct; 7(1):13780. PubMed ID: 29062024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An atomistic perspective on antibody-dependent cellular cytotoxicity quenching by core-fucosylation of IgG1 Fc N-glycans from enhanced sampling molecular dynamics.
    Harbison A; Fadda E
    Glycobiology; 2020 May; 30(6):407-414. PubMed ID: 31829411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.
    Kanda Y; Yamada T; Mori K; Okazaki A; Inoue M; Kitajima-Miyama K; Kuni-Kamochi R; Nakano R; Yano K; Kakita S; Shitara K; Satoh M
    Glycobiology; 2007 Jan; 17(1):104-18. PubMed ID: 17012310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood.
    Iida S; Kuni-Kamochi R; Mori K; Misaka H; Inoue M; Okazaki A; Shitara K; Satoh M
    BMC Cancer; 2009 Feb; 9():58. PubMed ID: 19226457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding.
    Borrok MJ; Luheshi NM; Beyaz N; Davies GC; Legg JW; Wu H; Dall'Acqua WF; Tsui P
    MAbs; 2015; 7(4):743-51. PubMed ID: 25970007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of FX
    Liu W; Padmashali R; Monzon OQ; Lundberg D; Jin S; Dwyer B; Lee YJ; Korde A; Park S; Pan C; Zhang B
    Biotechnol Prog; 2021 Jan; 37(1):e3061. PubMed ID: 32748555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The N-linked oligosaccharide at Fc gamma RIIIa Asn-45: an inhibitory element for high Fc gamma RIIIa binding affinity to IgG glycoforms lacking core fucosylation.
    Shibata-Koyama M; Iida S; Okazaki A; Mori K; Kitajima-Miyama K; Saitou S; Kakita S; Kanda Y; Shitara K; Kato K; Satoh M
    Glycobiology; 2009 Feb; 19(2):126-34. PubMed ID: 18952826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose.
    Ferrara C; Grau S; Jäger C; Sondermann P; Brünker P; Waldhauer I; Hennig M; Ruf A; Rufer AC; Stihle M; Umaña P; Benz J
    Proc Natl Acad Sci U S A; 2011 Aug; 108(31):12669-74. PubMed ID: 21768335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced Effector Functions Due to Antibody Defucosylation Depend on the Effector Cell Fcγ Receptor Profile.
    Bruggeman CW; Dekkers G; Bentlage AEH; Treffers LW; Nagelkerke SQ; Lissenberg-Thunnissen S; Koeleman CAM; Wuhrer M; van den Berg TK; Rispens T; Vidarsson G; Kuijpers TW
    J Immunol; 2017 Jul; 199(1):204-211. PubMed ID: 28566370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Site-Selective Chemoenzymatic Modification on the Core Fucose of an Antibody Enhances Its Fcγ Receptor Affinity and ADCC Activity.
    Li C; Chong G; Zong G; Knorr DA; Bournazos S; Aytenfisu AH; Henry GK; Ravetch JV; MacKerell AD; Wang LX
    J Am Chem Soc; 2021 May; 143(20):7828-7838. PubMed ID: 33977722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-receptor interactions mediate antibody-dependent cellular cytotoxicity.
    Sun Y; Izadi S; Callahan M; Deperalta G; Wecksler AT
    J Biol Chem; 2021 Jul; 297(1):100826. PubMed ID: 34044019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulating IgG effector function by Fc glycan engineering.
    Li T; DiLillo DJ; Bournazos S; Giddens JP; Ravetch JV; Wang LX
    Proc Natl Acad Sci U S A; 2017 Mar; 114(13):3485-3490. PubMed ID: 28289219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.